ENAGenomicsProfessor of Genetics, and Pathology & Laboratory Medicine Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hillhttps://www.ebi.ac.uk/ena/browser/view/PRJNA286743Homo sapiensGene expression profiling of the downstream transcriptional changes induced by ESR1 fusion genes observed in human breast tumors resistant to hormone therapy Overall design: Experimental T47D cells stably expressing ESR1 fusion genes (or T47D cells treated with estradiol) vs. T47D cells expressing YFPENANr3a1, Therapy, esr1, Estrogenic Agents, XER, Estrogen Receptor, Materials, Effects, Compounds, esr1b, estrogenes, esr1a, Oestrogene, AA420328, Gene, estrogene, Estrogen Receptor Agonists, Estra, Receptor Agonists, ER[a], SAD3, Cistrons, T-47D, xlERalpha1, xlERalpha2, transfect, T47-D cell, estrogens, estrogeno, ER, RAD31, Genetic Materials, Oestrogen, Era, Agonists, Estrogenic Effects, xesr-1, Estrogen Effects, Genetic Material, oestrogen, Estrogenic Effect, treatment, AU041214, Estrogen, Genetic, estrogenes Hormon, NR3A1, ERalpha, ERa, ESTRR, estrogenos, Treatments, nr3a1, ESR, Esr, Agents, Transfections., Therapeutic, Material, ESR1, Estr, ERbeta, esr-1, Estrogen Effect, xesr1, oestrogene, disease management, Therapies, oestrogens, Cistron, Estrogenic Compounds, Treatment, T47D cell, RNESTROR, Estrogene, Estrogenic, ER-alpha, ESRA, oestrogenesHuman, Modern., human being, Man (Taxonomy), Homo sapiens, man, Man, human, Modern ManfalseHomo sapiensT47D cell line transfected with various ESR1 fusion genes (or with estrogen treatment), vs. YFP transfection alone2025-09-242015-06-14PRJNA286743GSE697749606